Epigenetically programmed resistance to chemo- and immuno-therapies.
Epigenetically programmed resistance to chemo- and immuno-therapies.
复制标题
DOI：
10.1016/bs.acr.2022.12.001
复制
发表时间：
2023
影响因子：
--
通讯作者：
Chiappinelli, Katherine B
中科院分区：
文献类型：
--
作者：
Walker, Reddick R;Rentia, Zainab;Chiappinelli, Katherine B
对癌症治疗的抗药性仍然是开发癌症治疗方法的主要障碍。虽然有希望的联合化疗和新的免疫疗法改善了患者的预后，但对这些治疗的耐药性仍然知之甚少。对表观基因组失调的新见解表明，它是如何促进肿瘤生长和抵抗治疗的。通过改变对基因表达的控制，肿瘤细胞可以逃避免疫细胞识别，忽略凋亡信号，并逆转化疗引起的DNA损伤。在本章中，我们总结了在癌症进展和治疗过程中使癌细胞存活的表观遗传重塑的数据，并描述了这些表观遗传变化是如何在临床上被靶向以克服耐药性的。
Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.
DOI：
10.1007/s12539-018-0285-4
发表时间：
2018-03
期刊：
Interdisciplinary sciences, computational life sciences
影响因子：
--
作者：
Cecotka A;Polanska J
通讯作者：
Polanska J